Curated News
By: NewsRamp Editorial Staff
March 10, 2026
Creatd Sells Flyte Stake to NYSE-Listed VTAK, Securing $12M in Cash and Equity
TLDR
- Creatd gains a strategic advantage by securing $12 million in cash and NYSE-listed equity, strengthening its balance sheet for pursuing a national exchange listing.
- Creatd sold its 80% stake in Flyte to VTAK for cash and convertible preferred stock, executing its strategy of incubating companies for public market listings.
- This transaction helps bridge the structural gap in middle-market companies, enabling more businesses to stabilize, scale, and create lasting value through institutional support.
- Creatd transformed Flyte from an OTC acquisition to an NYSE-listed exit in just one year through operational optimization and technology integration.
Impact - Why it Matters
This transaction demonstrates a viable alternative model for small-cap companies seeking growth and exchange listings without dilutive traditional financing. For investors, it highlights Creatd's potential as a specialized platform that identifies undervalued assets, applies operational expertise, and executes premium exits—creating shareholder value through strategic M&A rather than speculative trading. In a market where many micro-cap companies struggle with infrastructure gaps, Creatd's approach could signal a new pathway for sustainable growth in the sector, potentially influencing how turnaround investments are structured and valued.
Summary
Creatd, Inc. (OTCQB: CRTDD) has completed a strategic divestiture, selling its remaining 80% equity stake in its subsidiary Fly Flyte, Inc. to NYSE-listed Catheter Precision, Inc. (NYSE American: VTAK). The transaction, valued at approximately $12 million, delivers a significant boost to Creatd's financial position through a combination of cash and Convertible Preferred Stock in VTAK. This move aligns with Creatd's core business model of acquiring, optimizing, and preparing companies for public market listings, ultimately positioning Creatd as a major shareholder in a nationally-listed entity. The deal underscores Creatd's role as a turnaround-focused platform in the small-cap M&A space, leveraging its technology and AI-first infrastructure to help companies overcome structural hurdles.
The sale of Flyte, a technology-enabled regional air mobility company operating Cirrus Vision Jets, represents a successful execution of Creatd's incubation strategy. Acquired just a year prior, Flyte underwent a disciplined turnaround focused on operational optimization and revenue growth, specifically groomed for acquisition by a larger, exchange-listed platform like VTAK. CEO Jeremy Frommer emphasized that this transaction strengthens Creatd's balance sheet without relying on traditional financing structures, providing capital to advance the company's own goal of achieving a national exchange listing. The proceeds will support Creatd's continued expansion as it builds a portfolio of public and private investments across diversified industries.
Looking ahead, Creatd and VTAK will maintain a strategic relationship, collaborating on ongoing aviation and eVTOL logistics platform development. This partnership highlights the enduring value created through Creatd's model. For more information, stakeholders can visit the company's website via this trusted press release distribution service. The transaction not only validates Creatd's acquisition and incubation approach but also addresses a perceived gap in the middle market, where many public companies lack the necessary infrastructure to reach their full potential. By stabilizing and scaling businesses like Flyte, Creatd aims to create lasting value for its shareholders while institutionalizing its unique platform in the micro-cap investment landscape.
Source Statement
This curated news summary relied on content disributed by PRISM Mediawire. Read the original source here, Creatd Sells Flyte Stake to NYSE-Listed VTAK, Securing $12M in Cash and Equity
